$42.17
-0.600 (-1.40%)
At Close: Jul 17, 2025
Ionis Pharmaceuticals Earnings Calls
Jul 01, 2025
(Upcoming)
Release date | Aug 07, 2025 |
EPS estimate | $0.190 |
EPS actual | - |
Revenue estimate | 270.896M |
Revenue actual | - |
Expected change | +/- 6.94% |
Mar 31, 2025
-$0.750 (32.43%)
Release date | Apr 30, 2025 |
EPS estimate | -$1.11 |
EPS actual | -$0.750 |
EPS Surprise | 32.43% |
Revenue estimate | 150.586M |
Revenue actual | 131.612M |
Revenue Surprise | -12.60% |
Dec 31, 2024
-$0.660 (39.45%)
Release date | Feb 19, 2025 |
EPS estimate | -$1.09 |
EPS actual | -$0.660 |
EPS Surprise | 39.45% |
Revenue estimate | 131.138M |
Revenue actual | 226.576M |
Revenue Surprise | 72.78% |
Sep 30, 2024
-$0.95 (18.10%)
Release date | Nov 06, 2024 |
EPS estimate | -$1.16 |
EPS actual | -$0.95 |
EPS Surprise | 18.10% |
Revenue estimate | 144.44M |
Revenue actual | 134M |
Revenue Surprise | -7.23% |
Last 4 Quarters for Ionis Pharmaceuticals
Below you can see how IONS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Sep 30, 2024
Beat
Release date | Nov 06, 2024 |
Price on release | $39.04 |
EPS estimate | -$1.16 |
EPS actual | -$0.95 |
EPS surprise | 18.10% |
Date | Price |
---|---|
Oct 31, 2024 | $38.39 |
Nov 01, 2024 | $38.76 |
Nov 04, 2024 | $38.44 |
Nov 05, 2024 | $38.80 |
Nov 06, 2024 | $39.04 |
Nov 07, 2024 | $38.46 |
Nov 08, 2024 | $39.19 |
Nov 11, 2024 | $38.88 |
Nov 12, 2024 | $37.77 |
4 days before | 1.69% |
4 days after | -3.25% |
On release day | -1.49% |
Change in period | -1.62% |
Dec 31, 2024
Beat
Release date | Feb 19, 2025 |
Price on release | $31.81 |
EPS estimate | -$1.09 |
EPS actual | -$0.660 |
EPS surprise | 39.45% |
Date | Price |
---|---|
Feb 12, 2025 | $30.84 |
Feb 13, 2025 | $30.35 |
Feb 14, 2025 | $31.04 |
Feb 18, 2025 | $31.95 |
Feb 19, 2025 | $31.81 |
Feb 20, 2025 | $32.69 |
Feb 21, 2025 | $32.32 |
Feb 24, 2025 | $31.89 |
Feb 25, 2025 | $31.85 |
4 days before | 3.15% |
4 days after | 0.126% |
On release day | 2.79% |
Change in period | 3.27% |
Mar 31, 2025
Beat
Release date | Apr 30, 2025 |
Price on release | $30.71 |
EPS estimate | -$1.11 |
EPS actual | -$0.750 |
EPS surprise | 32.43% |
Date | Price |
---|---|
Apr 24, 2025 | $29.57 |
Apr 25, 2025 | $29.70 |
Apr 28, 2025 | $29.74 |
Apr 29, 2025 | $29.81 |
Apr 30, 2025 | $30.71 |
May 01, 2025 | $31.71 |
May 02, 2025 | $32.78 |
May 05, 2025 | $33.65 |
May 06, 2025 | $31.86 |
4 days before | 3.86% |
4 days after | 3.74% |
On release day | 3.26% |
Change in period | 7.74% |
Jul 01, 2025
(Upcoming)
Release date | Aug 07, 2025 |
Price on release | - |
EPS estimate | $0.190 |
EPS actual | - |
Date | Price |
---|---|
Jul 11, 2025 | $41.73 |
Jul 14, 2025 | $42.55 |
Jul 15, 2025 | $42.00 |
Jul 16, 2025 | $42.77 |
Jul 17, 2025 | $42.17 |
Ionis Pharmaceuticals Earnings Call Transcript Summary of Q1 2025
Ionis First Quarter 2025 Earnings Call Summary for Investors
Key Highlights:
- Financial Guidance Upgrades:
- Ionis has raised its 2025 financial guidance across all metrics due to strong first-quarter performance and strategic licensing transactions.
- The revenue forecast is now between $725 million and $750 million, reflecting over 20% growth. For the first quarter, Ionis reported $132 million in revenue, a 10% year-over-year increase.
- Successful Product Launches:
- TRYNGOLZA: Launched as the first FDA-approved treatment for familial chylomicronemia syndrome (FCS), generating over $6 million in sales in its first full quarter. Strong initial uptake was noted due to effective conversion of existing patients and new patient identification efforts.
- Upcoming Launches:
- Donidalorsen for hereditary angioedema (HAE) is on track for an anticipated launch in Q3 2025.
- Olezarsen for severe hypertriglyceridemia (sHTG) is pushing towards Phase III results expected in Q3 2025.
- Pipeline Development:
- Key upcoming data readouts include those from two Phase III trials (CORE and CORE2) for olezarsen, which are highly anticipated and could reshape treatment approaches in sHTG.
- Plans to generate peak sales exceeding $3 billion from Ionis owned products and $2 billion from partnered programs in development.
- Market Strategies and Projections:
- The company is strategically positioning to convert FCS patients before entering the broader sHTG market, expecting to commercialize TRYNGOLZA for approximately 1.5 to 2 years prior to launching olezarsen.
- Ionis aims to enhance patient identification for FCS through increased physician awareness and education, establishing a robust base ahead of future product launches.
- Regulatory Environment and Market Dynamics:
- Ionis is monitoring changes in FDA regulations and new tariff policies but currently reports no significant impacts on operations.
- Both commercial and clinical supplies are well-managed, with sufficient stock for upcoming launches.
- Commercial Expansion:
- Significant emphasis on building strong patient support programs and improving accessibility for existing patients through payer engagement.
- Notable revenue growth anticipated from global expansions of partners for WAINUA and other products.
Overall, Ionis demonstrates strong financial performance amidst a challenging regulatory landscape, backed by a promising product pipeline and strategic market positioning. Investors should note the potential for revenue growth driven by both existing and upcoming launches.
Ionis Pharmaceuticals Earnings History
Earnings Calendar
FAQ
When is the earnings report for IONS?
Ionis Pharmaceuticals (IONS) has scheduled its earnings report for Aug 07, 2025 before the markets open.
What is the IONS price-to-earnings (P/E) ratio?
IONS P/E ratio as of Jul 17, 2025 (TTM) is -14.82.
What is the IONS EPS forecast?
The forecasted EPS (Earnings Per Share) for Ionis Pharmaceuticals (IONS) for the first fiscal quarter 2025 is $0.190.
What are Ionis Pharmaceuticals's retained earnings?
On its balance sheet, Ionis Pharmaceuticals reported retained earnings of $131.61 million for the latest quarter ending Mar 31, 2025.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.